Foghorn Therapeutics (FHTX) Assets Average (2020 - 2026)

Foghorn Therapeutics has reported Assets Average for 7 years, with the latest figure at $210.1 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 22.56% year-over-year to $210.1 million; the trailing twelve-month figure through Mar 2026 stood at $210.1 million (down 22.56% YoY), and the FY2025 full-year result was $241.0 million, down 15.41% from the prior year.
• Assets Average for Q1 2026 stood at $210.1 million, up from $201.5 million in the prior quarter.
• The five-year high for Assets Average was $504.0 million in Q1 2022, with the low at $201.5 million in Q4 2025.
• Average Assets Average over 5 years is $325.3 million, with a median of $299.7 million recorded in 2023.
• Year-over-year, Assets Average soared 125.76% in 2022 and tumbled 32.3% in 2025.
• Tracing FHTX's Assets Average over 5 years: stood at $419.4 million in 2022, then slipped by 28.55% to $299.7 million in 2023, then decreased by 1.17% to $296.2 million in 2024, then sank by 31.96% to $201.5 million in 2025, then increased by 4.27% to $210.1 million in 2026.
• The last three Assets Average figures came in at $210.1 million (Q1 2026), $201.5 million (Q4 2025), and $215.6 million (Q3 2025), per Business Quant data.

Peer Comparison